Correlation Between Enlivex Therapeutics and ALK Abell

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Enlivex Therapeutics and ALK Abell at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Enlivex Therapeutics and ALK Abell into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Enlivex Therapeutics and ALK Abell AS, you can compare the effects of market volatilities on Enlivex Therapeutics and ALK Abell and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Enlivex Therapeutics with a short position of ALK Abell. Check out your portfolio center. Please also check ongoing floating volatility patterns of Enlivex Therapeutics and ALK Abell.

Diversification Opportunities for Enlivex Therapeutics and ALK Abell

0.84
  Correlation Coefficient

Very poor diversification

The 3 months correlation between Enlivex and ALK is 0.84. Overlapping area represents the amount of risk that can be diversified away by holding Enlivex Therapeutics and ALK Abell AS in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on ALK Abell AS and Enlivex Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Enlivex Therapeutics are associated (or correlated) with ALK Abell. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of ALK Abell AS has no effect on the direction of Enlivex Therapeutics i.e., Enlivex Therapeutics and ALK Abell go up and down completely randomly.

Pair Corralation between Enlivex Therapeutics and ALK Abell

Given the investment horizon of 90 days Enlivex Therapeutics is expected to under-perform the ALK Abell. In addition to that, Enlivex Therapeutics is 1.82 times more volatile than ALK Abell AS. It trades about -0.01 of its total potential returns per unit of risk. ALK Abell AS is currently generating about 0.04 per unit of volatility. If you would invest  1,400  in ALK Abell AS on September 20, 2024 and sell it today you would earn a total of  805.00  from holding ALK Abell AS or generate 57.5% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthStrong
Accuracy99.8%
ValuesDaily Returns

Enlivex Therapeutics  vs.  ALK Abell AS

 Performance 
       Timeline  
Enlivex Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Enlivex Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's essential indicators remain fairly stable which may send shares a bit higher in January 2025. The latest fuss may also be a sign of long-term up-swing for the venture sophisticated investors.
ALK Abell AS 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days ALK Abell AS has generated negative risk-adjusted returns adding no value to investors with long positions. Despite fragile performance in the last few months, the Stock's essential indicators remain nearly stable which may send shares a bit higher in January 2025. The current disturbance may also be a sign of long-run up-swing for the company stockholders.

Enlivex Therapeutics and ALK Abell Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Enlivex Therapeutics and ALK Abell

The main advantage of trading using opposite Enlivex Therapeutics and ALK Abell positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Enlivex Therapeutics position performs unexpectedly, ALK Abell can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ALK Abell will offset losses from the drop in ALK Abell's long position.
The idea behind Enlivex Therapeutics and ALK Abell AS pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.

Other Complementary Tools

Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes